First-in-Human Phase I Clinical Trials

• CT041 CT041 Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG1 for recurrent glioblastoma Ryuta Saito, Fumiharu Ohka, Yohei Mineharu, Makoto Ohno, Miho Suzuki, Keiko Shinjo, Shoichi Deguichi, Yoshiki Shiba, Aya Sato, Yoshiki Arakawa, Yoshitaka Narita, Shiro Akinaga, Yutaka Kondo
• CT042 CT042 First-in-human trial of E-SYNC T-cells, an autologous anti-EGFRvIII SynNotch receptor-induced anti-EphA2/IL13Ra2 CAR T-cells, in adult patients with EGFRvIII+ glioblastoma Payal B. Watchmaker, Jennifer L. Clarke, Ricardo Almeida, Akane Yamamichi, Abigail Hansen, Harika T. Gopi, Karishma Kumar-Wessel, Megna Reddy, David Y. Oh, Jacob S. Young, Nicholas Butowski, Nancy A. Oberheim Bush, Jennie W. Taylor, John de Groot, Joanna Phillips, Annette M. Molinaro, Brain R. Shy, Wendell Lim, Hideho Okada
• CT043 · PDF Androgen receptor inhibition to overcome taxane resistance in AR-positive metastatic TNBC: Interim results of the 4CAST Phase 1b trial Jia Liu, Rasha Cosman, Sarah Childs, Jordan E. Cohen, Anthony Rodrigues, Thomas Hansen, Belinda E. Kiely, Julia Chen, Anuradha Pala, Geeta Sandhu, Juliet Ho, Sandunika Warakulasuriya, Doha Elgundi, Hao-Wen Sim, Robert Kent, Chloe Martin, Elizabeth M. Woodson, Christine L. Chaffer, Rachel Dear
• CT044 · PDF A phase 1B investigator-initiated trial of niraparib lead-in, followed by niraparib plus dostarlimab for metastatic BRCA1/2 -mutated breast, tubo-ovarian, and pancreatic cancers Elizabeth M. Swisher, Andrew Coveler, Kalyan Banda, Lynn Symonds, Isabel Rodriguez, Hannah H. Lee, Reina Hibbert, Jeniece Hensel, Harini Ramachandran, Tiffany N. Jones, Kelsey Baker, Mary Redman, Jennifer Specht
• CT045 · PDF Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer Steven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays, Nathalie LeVasseur, Andreas Varkaris, William Randolph, Karunya Srinivasan, Shannon McCue, Zhenming Shun, Ke Liu, Zhen Su, Kevin Chin, Virginia Kaklamani, Kelly McCann, Erika Hamilton
• CT046 · PDF A first-in-class HER2-targeted radiopharmaceutical therapy: Initial findings from the Phase 0/1 HEAT trial of 177Lu-RAD202 in HER2+ advanced solid tumors Aviral Singh, Udit Nindra, Ian Swainson, Dimitris Voliotis, Veronica Wong
• CT047 · PDF Effects of Maackia amurensis seed lectin (MASL) on OSCC cell morphology, PDPN expression, viability, and motility in a phase 1 clinical trial Ariel C. Yin, Cayla J. Holdcraft, Tyler J. Hellmig, Eamonn J. Brace, David I. Suster, Alan J. Shienbaum, Dylan Roden, Evelyne Kalyousef, Ghayoour Mir, Eugenio Capitle, Soly Baredes, Rabie Shanti, Mika K. Kaneko, Yukinari Kato, Hisataka Kobayashi, Aki Furusawa, Mahnaz Fatahzadeh, Gary S. Goldberg
• CT048 · PDF A first in human, dose escalation (DE) and biomarker cohort expansion (BCE) of IMT-009 (IMT) in advanced cancer and Phase 1b (Ph1b) combination with fruquintinib (F) in microsatellite stable colorectal cancer (MSS CRC) Susanna V. Ulahannan, Melissa Johnson, Jason T. Henry, Shruti Malu, Sudhir Manda, Manish R. Patel, Shivaani Kummar, Adwitiya Kar, Alexander Spira, Vivian Cline, Ana L. Costa, Sarah Djeddi, Diane Stebbins, Nicholas Ferenc, Lucy Chen, James E. Wooldridge, Cesar A. Perez
• CT050 · PDF Preliminary clinical results of TAVO412, an anti-EGFR/cMET/VEGF multispecific antibody, in patients with advanced or metastatic solid tumors Mark Chiu, Yanjiao Yu, Mira Zhao, Wei Zhang, Hong Xie, Chao Han
• CT051 · PDF From preclinical models to first-in-human evaluation of STC-1010 immunotherapy in unresectable advanced colorectal cancer Diego Tosi, Antoine Italiano, Antoine Hollebecque, Benoît You, Philippe Cassier, Francesco Sclafani, David Tougeron, Eric Christenson, Céline Gongora, Iseulys Richert, George Alzeeb, Paul Marteau, Marion Brun, Leila Feki, Lionel Chalus, Benoit Pinteur, Paul Bravetti, Sarah Kerbouche, Corinne Tortorelli, François Ghiringhelli
• CT052 · PDF Proof of mechanism from a phase 1, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LRK-4189 in healthy subjects Krista Goodman, Eva d'Hennezel, Morgan O'Shea, Melvyn Chow, Julie Arnold, Sujen Lai, Catherine Sabatos-Peyton, Amber Morgan, Phillipa Graham, Alice Bexon, Sharan Sidhu, Eric Van Cutsem
• CT053 · PDF A phase 1 clinical trial of CT-01, a dual degrader of GSPT1 and NEK7, alone or in combination with everolimus for the treatment of hepatocellular carcinoma Anna Maria Serwotka-Suszczak, Andrew Saunders, Krzysztofa Odrzywol, Robert Dyjas, Piotr Kowalczyk, Przemysław Glaza, Roman Pluta, Karolina Brodzik, Joanna Lis, Olga Makowska, Joanna Majkut, Martyna Mianowska, Paulina Rozborska, Anna Sawicka, Marta Sowała, Agata Śnieżewska, Katarzyna Kaczanowska, Jan Klajn, Grzegorz Statkiewicz, Arkadiusz Zając, Katarzyna Brach, Michał Biśta, Paweł Dobrzański, Sylvain Cottens, Michał Walczak
• CT054 · PDF Results from the phase 1b/2 Morpheus liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm Daneng Li, Edward Gane, Chih-Hung Hsu, Adam Burgoyne, Peter Luo, Songmao Zheng, Yan Li, Xiaohong She, Stanley Frankel, Jiping Zha, Ann-Lii Cheng
• CT055 · PDF Early clinical activity and tumor transcriptional modulation of AU409, a first-in-class transcription regulator, in advanced solid tumors and hepatocellular carcinoma: Results from two phase I studies Anthony El-Khoueiry, Anastasia Martynova, Diana Hanna, Jacob Thomas, Syma Iqbal, Sandra Algaze, Viwat Visuthikraisee, Brenton Louie, Gregory Luedtke, Xiaoyi Li, Pek Lum, Chi Leung Chiang
• CT056 · PDF Phase I study of intratumoral microdevices reveals heterogenous immune and apoptotic responses across distinct drug-treated regions in adenoid cystic carcinoma of the head and neck Fanni Santa, Joseph Kotler, Simon Chow, Sharath K. Bhagavatula, Vickie Y. Jo, Hannah Roth, Vincenzo Tarallo, Samantha E. Martin, Ellen Maloney, Wooseok Ahn, Glenn J. Hanna, Oliver Jonas
• CT057 · PDF Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody Jin Li, Weizheng Kou, Longhua Sun, Yanqiu Zhao, Rusen Zhao, Baozhong Wang, Shaozhang Zhou, Juan Li, Xuewen Liu, Jun Zhao, Dongqing Lv, Gaofeng Li, Junli Xue, Yong Fang, Daren Lin, Jianhua Shi, Yi Gong, Xia Qin, Yi Zuo, Erik H. Knelson, Weijuan Zhang, Caicun Zhou
• CT060 · PDF First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tumors with MAPK pathway mutations Yi-Long Wu, Michael Millward, Yanqiao Zhang, Matteo S. Carlino, Xian Wang, Amitesh Roy, Jun Zhang, Jun Zhao, Zhen Wang, Amy Weise, Debora Doroshow, Shaonan Wang, Zifei Fan, Rong Su, Jing Zhang, Jia Wang, Wenqian Wang, Cheng Chen, Qian Chen, Hui Wang, Zhijian Chen
• CT061 · PDF A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers Alexander Drilon, Jia Yu, Zhiyong He, Yongsheng Wang, Kejing Tang, Tianqing Chu, Shutan Liao, Junjun Zhang, Xinlong Zheng, Jaime Rubio-Perez, Matteo Repetto, Brendan Putz, Shengxiang Ren
• CT062 · PDF Single institution experience of the phase 1 expansion study of IK-595, a novel MEK-RAF molecular glue, in patients with NRAS/KRAS mutated advanced tumors Jennifer Brooke Valerin, April Choi, Connie Kang, Miranda Duron, Christine Choe, Katherine Kim, Trupti Lingaraj, David Damphousse, Farshid Dayyani
• CT063 · PDF An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 study Babar Bashir, Juan Martin-Liberal, Judy S. Wang, Raid Aljumaily, Bernard Doger de Spéville, Elena Garralda, Meredith McKean, Elisa Fontana, Hans Prenen, Daniel A. Peterson, Vienna Reichert, Xuemin Gu, Mengyao Li, Assunta De Rienzo, Alastair Greystoke
• CT064 · PDF Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumors Xingyun Cai, Jian Zhang, Yu Chen, Yanxia Shi, Wei Wang, Zhanhong Chen, Jiongjie Chen
• CT065 · PDF Preliminary safety, pharmacokinetics and pharmacodynamics of SGR-3515, a Wee1/Myt1 dual inhibitor from an ongoing Phase 1 study in participants with advanced solid tumors (SGR-3515-101) Stephanie Lheureux, Michael K. Gibson, Kathleen N. Moore, Wendel Naumann, Mohamad Salkeni, Pedro Hermida de Viveiros, Deborah Doroshow, David Miller, Vivek Subbiah, Ira Winer, Shaoxian Sun, Peter Skrdla, Francois Lafleur, Steven Pirie-Shepherd, Sarsvat Patel, Yi Zhang, Kevin Wu, Margaret Dugan, Patricia M. LoRusso
• CT066 · PDF Targeted hyperthermia induces immunogenic tumor remodeling and demonstrates early clinical response in immunotherapy-refractory metastatic melanoma Barry Kennedy, Carman Giacomantonio, Kate Clark, Julie Jordan, Cheryl Dean, Nick Cheverie, Kelly Corscadden, Caitlin Gormley, Geetha Subramanian, Erin Noftall, Alexander Roth

在会议检索中浏览本分会场